←Back to Expert Scholars
Translational Medicine / 转化医学Pembrolizumab Clinical Development
Roger Dansey
MD
🏢Merck and Seagen🌐USA
Former Chief Medical Officer
55
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Roger Dansey helped lead the clinical development of pembrolizumab at Merck before joining Seagen where he directed antibody drug conjugate programs. His work has been central to advancing both checkpoint inhibitors and targeted biologics in oncology.
Share:
🧪Research Fields 研究领域
pembrolizumab trials
antibody drug conjugates
oncology drug development
hematology oncology
global development
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Roger Dansey 的研究动态
Follow Roger Dansey's research updates
留下邮箱，当我们发布与 Roger Dansey（Merck and Seagen）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment